AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7967324 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 64
Study 7967324 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 64
Study 3519097 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg fipexide daily
Number of subjects: 40
Study 3519097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30356442 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 40
Study 30356442 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 27449221 — intervention group
Group type: EXPERIMENTAL
Intervention: Kunxian capsules (0.6 g, three times per day) for 12 weeks
Number of subjects: 80
Study 27449221 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 80
Study 27449221 — intervention group
Group type: EXPERIMENTAL
Intervention: Kunxian capsules
Number of subjects: 80
Study 24958498 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth periodontal scaling during a single visit
Number of subjects: 273
Study 24958498 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 273
Study 22379070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction in children with severe asthma (n=42)
Number of subjects: 79
Study 22379070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction in children with mild to moderate asthma (n=17)
Number of subjects: 79
Study 22379070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction in children with asthma (both groups)
Number of subjects: 79
Study 20382279 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation (ES) combined with active ankle dorsiflexion while standing on a rocker board
Number of subjects: 15
Study 20382279 — intervention group
Group type: COMPARATOR
Intervention: General range of motion and strength exercises
Number of subjects: 15
Study 18427362 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 20
Study 18427362 — intervention group
Group type: COMPARATOR
Intervention: Conventional quadrant therapy
Number of subjects: 20
Study 16167471 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 (four different lactobacilli preparations with 10^10 CFU and prebiotics)
Number of subjects: 62
Study 16167471 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000
Number of subjects: 62
Study 16167471 — intervention group
Group type: COMPARATOR
Intervention: Control (only prebiotics)
Number of subjects: 62
Study 12598350 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimen (docetaxel 100 mg/m2, doxorubicin 75 mg/m2, cycle-by-cycle alternating)
Number of subjects: 106
Study 12598350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen (docetaxel 100 mg/m2, doxorubicin 75 mg/m2, sequential for four cycles)
Number of subjects: 106
Study 10492276 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc DTPA aerosol inhalation lung scintigraphy
Number of subjects: 13
Study 8894572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefaclor
Number of subjects: 39
Study 8894572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8894572 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 39
Study 1856932 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary occlusion of hypogastric arteries
Number of subjects: 130
Study 1856932 — intervention group
Group type: COMPARATOR
Intervention: No temporary occlusion of hypogastric arteries
Number of subjects: 130
Study 6357076 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 50
Study 6357076 — intervention group
Group type: COMPARATOR
Intervention: Carboxypenicillin-aminoglycoside combination
Number of subjects: 50
Study 31215755 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (100 mg single dose or 30, 80, and 120 mg multiple doses once daily for 28 days)
Number of subjects: 0
Study 31215755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27555381 — intervention group
Group type: EXPERIMENTAL
Intervention: atDCS+SSRI
Number of subjects: 40
Study 27555381 — intervention group
Group type: COMPARATOR
Intervention: atDCS+placebo
Number of subjects: 40
Study 27555381 — intervention group
Group type: COMPARATOR
Intervention: sham+placebo
Number of subjects: 40
Study 27555381 — intervention group
Group type: COMPARATOR
Intervention: sham+SSRI
Number of subjects: 40
Study 27555381 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 40
Study 25978402 — intervention group
Group type: EXPERIMENTAL
Intervention: PASSAGE Program (intervention group)
Number of subjects: 43
Study 25978402 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Group (control)
Number of subjects: 43
Study 22676966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 30
Study 21239979 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting management
Number of subjects: 336
Study 18780164 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release formulation with immediate release element
Number of subjects: 4
Study 18780164 — intervention group
Group type: EXPERIMENTAL
Intervention: Four formulations of Galantamine
Number of subjects: 4
Study 16429213 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with fiber (SF)
Number of subjects: 179
Study 16429213 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based formula (CM)
Number of subjects: 179
Study 15333386 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface‐rewarming group (using the Arctic Sun thermoregulatory system; n = 7)
Number of subjects: 13
Study 15333386 — intervention group
Group type: COMPARATOR
Intervention: Control standard rewarming group (n = 6)
Number of subjects: 13
Study 10695942 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg plus Amoxicillin 500 mg (M+A)
Number of subjects: 46
Study 10695942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9343284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoantigenic milk formula
Number of subjects: 36
Study 9343284 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 36
Study 9343284 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula feeding
Number of subjects: 36
Study 8404931 — intervention group
Group type: EXPERIMENTAL
Intervention: Early plasma atrial natriuretic factor (ANF) levels
Number of subjects: 90
Study 8404931 — intervention group
Group type: EXPERIMENTAL
Intervention: Early plasma atrial natriuretic factor (ANF) levels in patients without effort-associated ischaemia
Number of subjects: 90
Study 3633511 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic intermittent compression (EPIC) for 30 minutes at 40 torr
Number of subjects: 35
Study 3633511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPIC)
Number of subjects: 35
Study 29695370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinge Health digital care program for chronic knee pain (12-week intervention including sensor-guided exercise therapy, education, cognitive behavioral therapy, weight loss, and psychosocial support)
Number of subjects: 162
Study 29695370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinge Health digital care program for chronic knee pain
Number of subjects: 162
Study 29695370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinge Health digital care program for chronic knee pain (per protocol analysis)
Number of subjects: 162
Study 29695370 — intervention group
Group type: COMPARATOR
Intervention: Control group (received three education pieces regarding self-care for chronic knee pain)
Number of subjects: 162
Study 28863052 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth and motivational interviewing (MI) counseling
Number of subjects: 32
Study 28863052 — intervention group
Group type: COMPARATOR
Intervention: Control group smoking cessation assistance
Number of subjects: 32
Study 28863052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups' experiences
Number of subjects: 32
Study 28863052 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth and MI
Number of subjects: 32
Study 28863052 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and increased awareness of smoking behaviors
Number of subjects: 32
Study 25829397 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 238
Study 25829397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 25829397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 3 EGFR mut(+) cfDNA
Number of subjects: 238
Study 25829397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 3 EGFR mut(−) cfDNA
Number of subjects: 238
Study 23109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell (PBSC) donation
Number of subjects: 9494
Study 23109243 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow (BM) donation
Number of subjects: 9494
Study 21530339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch (5%)
Number of subjects: 0
Study 21530339 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 18975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 1072
Study 18975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 1072
Study 18975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 240 mg
Number of subjects: 1072
Study 18975369 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 or 100 mg)
Number of subjects: 1072
Study 18975369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 18975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg (impaired renal function)
Number of subjects: 1072
Study 18975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg (impaired renal function)
Number of subjects: 1072
Study 18975369 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 240 mg (impaired renal function)
Number of subjects: 1072
Study 18975369 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 100 mg (impaired renal function)
Number of subjects: 1072
Study 16472565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 500 mg twice a day for 5 days
Number of subjects: 68
Study 16472565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 12577155 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive airway suctioning (MIAS)
Number of subjects: 208
Study 12577155 — intervention group
Group type: COMPARATOR
Intervention: Routine endotracheal suctioning (RES)
Number of subjects: 208
Study 11141229 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 529
Study 11141229 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 529
Study 9741041 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective binge episodes
Number of subjects: 0
Study 9741041 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective binge episodes
Number of subjects: 0
Study 7977957 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection plus elective supraomohyoid neck dissection (RSOND)
Number of subjects: 67
Study 7977957 — intervention group
Group type: COMPARATOR
Intervention: Resection alone (RA)
Number of subjects: 67
Study 2498657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surgical ligation of the ductus arteriosus on the day of birth (n = 40)
Number of subjects: 84
Study 31981802 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Amelioration Program for Youth (ASAP-Y)
Number of subjects: 88
Study 31981802 — intervention group
Group type: COMPARATOR
Intervention: General health information control condition
Number of subjects: 88
Study 28409233 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (WBI)
Number of subjects: 84
Study 28409233 — intervention group
Group type: COMPARATOR
Intervention: Printed manual intervention (PMI)
Number of subjects: 84
Study 28409233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WBI and PMI
Number of subjects: 84
Study 25776839 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/day)
Number of subjects: 30
Study 25776839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21142787 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching with CO(2) laser
Number of subjects: 50
Study 21142787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50‐μm Al(2)O(3)
Number of subjects: 50
Study 21142787 — intervention group
Group type: EXPERIMENTAL
Intervention: Coating with titanium nitride (TiAlN)
Number of subjects: 50
Study 21142787 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicoating by Silano‐Pen
Number of subjects: 50
Study 21142787 — intervention group
Group type: COMPARATOR
Intervention: Control (unaltered abutments)
Number of subjects: 50
Study 20828371 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PROP, n=10)
Number of subjects: 20
Study 20828371 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL, n=10)
Number of subjects: 20
Study 20108651 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 236
Study 20108651 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 236
Study 17953475 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ (40/12.5 mg/day for 4 weeks; then 40/25 mg/day for 4 weeks)
Number of subjects: 190
Study 17953475 — intervention group
Group type: COMPARATOR
Intervention: Benazepril plus amlodipine besylate (20/5 mg/day for 4 weeks; then 20/10 mg/day for 4 weeks)
Number of subjects: 190
Study 17953475 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ
Number of subjects: 190
Study 17953475 — intervention group
Group type: COMPARATOR
Intervention: Benazepril plus amlodipine besylate
Number of subjects: 190
Study 15492993 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography from age 40
Number of subjects: 160861
Study 15492993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no annual mammography)
Number of subjects: 160861
Study 11209625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 205
Study 11209625 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley catheter
Number of subjects: 205
Study 11209625 — intervention group
Group type: COMPARATOR
Intervention: Combination prostaglandin E2 (PGE2) gel and Foley catheter
Number of subjects: 205
Study 9573676 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intensification therapy
Number of subjects: 108
Study 9573676 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without delayed intensification therapy
Number of subjects: 108
Study 7826905 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-IFN
Number of subjects: 177
Study 7826905 — intervention group
Group type: COMPARATOR
Intervention: splenectomy after achieving PR
Number of subjects: 177
Study 29979362 — intervention group
Group type: EXPERIMENTAL
Intervention: Prineo closure (octyl-2-cyanoacrylate and adhesive mesh)
Number of subjects: 21
Study 29979362 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular closure
Number of subjects: 21
Study 27171112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2800 International Units per day for 8 weeks)
Number of subjects: 36
Study 27171112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24774351 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE intervention
Number of subjects: 242
Study 24774351 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 22542605 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine (0.5‐1.5mg/kg/day, n=30)
Number of subjects: 95
Study 22542605 — intervention group
Group type: EXPERIMENTAL
Intervention: Elental as an elemental diet (≥900 kcal/day, n=32)
Number of subjects: 95
Study 22542605 — intervention group
Group type: COMPARATOR
Intervention: None (control, n=33)
Number of subjects: 95
Study 20203342 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacarpal group
Number of subjects: 30
Study 20203342 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist group
Number of subjects: 30
Study 20203342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-forearm group
Number of subjects: 30
Study 18215600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose statin therapy
Number of subjects: 8659
Study 18215600 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose statin therapy
Number of subjects: 8659
Study 12957526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide plus salbutamol (IB+S)
Number of subjects: 20
Study 12957526 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide plus placebo (IB+P)
Number of subjects: 20
Study 12957526 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol plus placebo (S+P)
Number of subjects: 20
Study 12957526 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo (P+P)
Number of subjects: 20
Study 12541393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of doktarin ps cream (DC)
Number of subjects: 325
Study 12541393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ketoconazole cream (KEC)
Number of subjects: 325
Study 12541393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of clotrimazole ung (CU)
Number of subjects: 325
Study 12541393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of thymol alcohol (TA)
Number of subjects: 325
Study 12541393 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic intermittent impulsive treatment
Number of subjects: 325
Study 12541393 — intervention group
Group type: COMPARATOR
Intervention: Compound azoles drugs
Number of subjects: 325
Study 9057377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (100 mg/kg/day)
Number of subjects: 101
Study 9057377 — intervention group
Group type: COMPARATOR
Intervention: Combination of benzyl penicillin (100,000 units/kg/day) and chloramphenicol (100 mg/kg/day)
Number of subjects: 101
Study 1725546 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 1,500,000 U in 1 h
Number of subjects: 25
Study 1725546 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 250,000 U in 30 min followed by 100,000 U/h for 48 h
Number of subjects: 25
Study 1725546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6684446 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono) in combination with antibiotic therapy
Number of subjects: 30
Study 6684446 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy alone
Number of subjects: 30
Study 6684446 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 30
Study 30243422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered methadone (PCM)
Number of subjects: 300
Study 30243422 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 300
Study 27560200 — intervention group
Group type: EXPERIMENTAL
Intervention: Verion Image Guided System (first measurement)
Number of subjects: 150
Study 27560200 — intervention group
Group type: EXPERIMENTAL
Intervention: Verion Image Guided System (second measurement)
Number of subjects: 150
Study 27560200 — intervention group
Group type: EXPERIMENTAL
Intervention: Verion Image Guided System (third measurement)
Number of subjects: 150
Study 27560200 — intervention group
Group type: COMPARATOR
Intervention: IOLMaster 500
Number of subjects: 150
Study 27560200 — intervention group
Group type: COMPARATOR
Intervention: Lenstar LS900
Number of subjects: 150
Study 27560200 — intervention group
Group type: COMPARATOR
Intervention: Pentacam HR
Number of subjects: 150
Study 27560200 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 150
Study 24342685 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin (18 g of monensin/t of dry matter)
Number of subjects: 128
Study 24342685 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Starch (NS) with Monensin
Number of subjects: 128
Study 24342685 — intervention group
Group type: COMPARATOR
Intervention: Normal Starch (NS)
Number of subjects: 128
Study 24342685 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin (M)
Number of subjects: 128
Study 24342685 — intervention group
Group type: COMPARATOR
Intervention: Reduced Starch (RS)
Number of subjects: 128
Study 22340476 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT), 20,000 shock wave impulses in 10 sessions over a two-week period
Number of subjects: 80
Study 22340476 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 80
Study 20351356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact histatins in the AEP
Number of subjects: 0
Study 20351356 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally occurring histatins
Number of subjects: 0
Study 18383000 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg paroxetine
Number of subjects: 17
Study 18383000 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg amitriptyline
Number of subjects: 17
Study 18383000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15758533 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (100 mg/kg) plus phototherapy
Number of subjects: 60
Study 15758533 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy only (control group)
Number of subjects: 60
Study 11827921 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+)CD28(null) T cells from patients with unstable angina (UA)
Number of subjects: 0
Study 11827921 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 0
Study 11827921 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+)CD28(null) T cells
Number of subjects: 0
Study 11827921 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+)CD28(null) T cells pretreated with strontium
Number of subjects: 0
Study 10070909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 400 mg daily for 6 months
Number of subjects: 24